Towards Improving Treatment with Medicines
Increasingly sponsors of new drugs are integrating pharmacogenetics in their drug development programmes. The outcome of this integration will present challenges to the traditional paradigms for drug development, regulatory evaluation of safety and efficacy and clinical use of drugs. Ethical, legal and pharmacoeconomic issues are also expected to weigh in heavily. This report addresses many of these issues in detail.